NEW YORK, April 19, 2022 (Globe NEWSWIRE) — Pomerantz LLP is investigating promises on behalf of buyers of Cassava Sciences, Inc. (“Cassava” or the “Organization”) SAVA.   Such buyers are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation fears no matter whether Cassava and selected of its officers and/or administrators have engaged in securities fraud or other illegal organization methods. 

[Click here for information about joining the class action]

On April 18, 2022, The New York Periods released an short article entitled “Experts Query Knowledge Driving an Experimental Alzheimer’s Drug.”  The write-up dealt with Cassava’s experimental Alzheimer’s drug, simufilam, and described that a single of Cassava’s advisers, Dr. H.Y. Wang, experienced 5 papers he authored retracted from the scientific journal PLoS A single immediately after an in-depth investigation revealed “serious problems about the integrity and the dependability of the effects.” 

On this news, Cassava’s stock rate fell sharply through intraday trading on April 19, 2022.

Pomerantz LLP, with places of work in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as 1 of the leading companies in the spots of company, securities, and antitrust class litigation. Launched by the late Abraham L. Pomerantz, identified as the dean of the class motion bar, Pomerantz pioneered the field of securities course steps. Nowadays, much more than 85 years later, Pomerantz carries on in the custom he set up, preventing for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered several multimillion-greenback damages awards on behalf of course associates. See www.pomlaw.com

Speak to:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980



Source website link